Toggle navigation
Our Platform
Our Platform
Peptide Receptor Radionuclide Therapy
Peptide-Drug Conjugate Program
SOR-C13 TRPV6 Inhibitor
Science
Discovery
The Target: TRPV6
Mechanism of Action
Intellectual Property
About
Our Team
For Investors
News and Events
Resources
Contact
CLOSE
Toggle navigation
Our Platform
Our Platform
Peptide Receptor Radionuclide Therapy
Peptide-Drug Conjugate Program
SOR-C13 TRPV6 Inhibitor
Science
Discovery
The Target: TRPV6
Mechanism of Action
Intellectual Property
About
Our Team
For Investors
News and Events
Resources
Contact
October 2, 2019
Professor Jack Stewart, Chief Scientific Officer, explains the mechanism of action of Soricimed's lead drug candidate, SOR-C13.
iFrame is not supported!
Sign up to receive updates from Soricimed
Submit
Powered by Innovasium
